Search Articles — Sudonull

https://sudonull.com/react-test-automation-7-ai-agents

Learn how a multi-agent pipeline on Claude Code migrates tests from Enzyme to RTL. Mutations, review, integration into Git. For middle/senior dev.

https://sudonull.com/crispr-pencil-gene-therapy-n-1-saved-an-infant

Doctors edited a newborn's liver by assembling therapy for a unique mutation. Learn how CRISPR-pencil is changing regulation and the future of medicine.

https://sudonull.com/ai-ui-as-a-source-of-visual-mutations

Learn how AI-generated interfaces deliver visual innovations for designers. Mutation selection, workflow and limitations — a guide for middle/senior. Start applying right now.

https://sudonull.com/evolution-of-rag-genomes-and-cache-of-mcp-servers

Implementation of controlled evolution of RAG pipelines on MCP documents1c. Three layers of genomes, SQL models, mutation-evaluation cycle. For middle/senior dev. Study the code and architecture.

https://sudonull.com/oncolytics-biotech-immunotherapy-for-pancreatic-cancer-asco-2026

Oncolytics Biotech data at ASCO 2026: pelareorep virus activates T cells against mutant KRAS in pancreatic cancer. Learn about the breakthrough in treating 'cold' tumors.

https://ymaho.com/personalized-crispr-therapy-saved-an-infant-in-vivo-breakthrough

A child with the ultra-rare CPS1 mutation survived thanks to personalized CRISPR therapy in 6 months. Learn about the breakthrough in genetic engineering and N-of-1 platforms.

https://ymaho.com/rna-therapy-for-hereditary-cardiomyopathy-breakthrough-in-treating-pln-r14del

Scientists reversed cellular defects in PLN R14del mutation using RNA therapy. Learn about a new approach to etiotropic treatment of heart failure. Read details.

https://ymaho.com/vepdegestrant-the-first-breast-cancer-protein-degrader

FDA approved vepdegestrant — the first PROTAC degrader for breast cancer with ESR1 mutation. Learn how it destroys resistance and what will change in therapy. Details here.

https://ymaho.com/sunvozertinib-outperforms-chemotherapy-in-egfr-exon20ins-lung-cancer

NEJM: oral sunvozertinib reduces the risk of progression by 35% in NSCLC with EGFR exon20ins mutation. Full analysis of efficacy, toxicity and drug availability. Learn more.

https://ymaho.com/gene-therapy-for-otof-deafness-hearing-restoration

FDA approved the first gene therapy for hereditary deafness Otarmeni. Learn how a single injection restores hearing in OTOF mutation and changes the market.

https://ymaho.com/gedatolisib-phase-3-success-in-pik3ca-mutated-cancer

Gedatolisib met the endpoint in the VIKTORIA-1 study, surpassing the standard of care. Learn how this will change the market. Read the detailed analysis.

https://ymaho.com/dream-protein-key-regulator-of-aging-and-mutations-nature-aging

Nature Aging study: the DREAM complex controls aging and mutational burden. How reducing its activity extends lifespan and protects against Alzheimer's disease. Read.

https://ymaho.com/sbs5-and-sbs18-signatures-oxidative-mutations-from-smoking

Whole-exome sequencing revealed SBS5 and SBS18 mutations in smokers' cells. Learn about irreversible changes, lung cancer risk, and new diagnostic tests. Read details.

https://ymaho.com/ai-predicts-brain-cancer-without-biopsy-using-pet-ct

Multimodal AI model based on graph neural networks analyzes PET/CT and predicts glioma mutations with >95% accuracy. Non-invasive diagnosis without biopsy. Learn more.

https://ymaho.com/fda-approved-the-first-gene-therapy-for-hereditary-deafness

Regeneron's Otarmeni restores hearing to normal in 42% of patients. The therapy treats OTOF gene mutations with a single injection. Learn how AAV vector technology has for the first time restored the ability to hear a whisper.